Logo image of AAPG

ASCENTAGE PHARMA GR-ADR (AAPG) Stock Fundamental Analysis

NASDAQ:AAPG - Nasdaq - ADR - Currency: USD

19.93  +0.49 (+2.52%)

Fundamental Rating

3

Overall AAPG gets a fundamental rating of 3 out of 10. We evaluated AAPG against 572 industry peers in the Biotechnology industry. AAPG may be in some trouble as it scores bad on both profitability and health. AAPG shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AAPG had negative earnings in the past year.
In the past year AAPG has reported a negative cash flow from operations.
In the past 5 years AAPG always reported negative net income.
In the past 5 years AAPG always reported negative operating cash flow.
AAPG Yearly Net Income VS EBIT VS OCF VS FCFAAPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -500M -1B

1.2 Ratios

AAPG has a Return On Assets of -11.60%. This is amongst the best in the industry. AAPG outperforms 86.74% of its industry peers.
AAPG's Return On Equity of -47.01% is fine compared to the rest of the industry. AAPG outperforms 67.54% of its industry peers.
Industry RankSector Rank
ROA -11.6%
ROE -47.01%
ROIC N/A
ROA(3y)-31.61%
ROA(5y)-51.37%
ROE(3y)-603.83%
ROE(5y)-411.56%
ROIC(3y)N/A
ROIC(5y)N/A
AAPG Yearly ROA, ROE, ROICAAPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 -1K -1.5K

1.3 Margins

Looking at the Gross Margin, with a value of 96.96%, AAPG belongs to the top of the industry, outperforming 96.68% of the companies in the same industry.
In the last couple of years the Gross Margin of AAPG has declined.
The Profit Margin and Operating Margin are not available for AAPG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5Y-2.92%
AAPG Yearly Profit, Operating, Gross MarginsAAPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

1

2. Health

2.1 Basic Checks

AAPG has more shares outstanding than it did 1 year ago.
AAPG has more shares outstanding than it did 5 years ago.
AAPG has a worse debt/assets ratio than last year.
AAPG Yearly Shares OutstandingAAPG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
AAPG Yearly Total Debt VS Total AssetsAAPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

2.2 Solvency

AAPG has an Altman-Z score of 0.99. This is a bad value and indicates that AAPG is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.99, AAPG is in the better half of the industry, outperforming 67.02% of the companies in the same industry.
A Debt/Equity ratio of 1.42 is on the high side and indicates that AAPG has dependencies on debt financing.
AAPG has a worse Debt to Equity ratio (1.42) than 80.80% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.42
Debt/FCF N/A
Altman-Z 0.99
ROIC/WACCN/A
WACCN/A
AAPG Yearly LT Debt VS Equity VS FCFAAPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 1B -1B 2B

2.3 Liquidity

A Current Ratio of 1.84 indicates that AAPG should not have too much problems paying its short term obligations.
With a Current ratio value of 1.84, AAPG is not doing good in the industry: 77.31% of the companies in the same industry are doing better.
AAPG has a Quick Ratio of 1.83. This is a normal value and indicates that AAPG is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.83, AAPG is not doing good in the industry: 75.74% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.83
AAPG Yearly Current Assets VS Current LiabilitesAAPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

AAPG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 61.93%, which is quite impressive.
Looking at the last year, AAPG shows a very strong growth in Revenue. The Revenue has grown by 251.85%.
The Revenue has been growing by 100.76% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)61.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%138.12%
Revenue 1Y (TTM)251.85%
Revenue growth 3Y161.25%
Revenue growth 5Y100.76%
Sales Q2Q%477.25%

3.2 Future

AAPG is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.48% yearly.
Based on estimates for the next years, AAPG will show a very strong growth in Revenue. The Revenue will grow by 39.38% on average per year.
EPS Next Y61.78%
EPS Next 2Y-2.19%
EPS Next 3Y46.48%
EPS Next 5YN/A
Revenue Next Year120.73%
Revenue Next 2Y11.94%
Revenue Next 3Y82.7%
Revenue Next 5Y39.38%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
AAPG Yearly Revenue VS EstimatesAAPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AAPG Yearly EPS VS EstimatesAAPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AAPG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AAPG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AAPG Price Earnings VS Forward Price EarningsAAPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AAPG Per share dataAAPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

AAPG's earnings are expected to grow with 46.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.19%
EPS Next 3Y46.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AAPG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASCENTAGE PHARMA GR-ADR

NASDAQ:AAPG (3/7/2025, 8:03:01 PM)

19.93

+0.49 (+2.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)03-26 2025-03-26/amc
Inst Owners7.36%
Inst Owner ChangeN/A
Ins Owners13.63%
Ins Owner ChangeN/A
Market Cap1.74B
Analysts87.69
Price TargetN/A
Short Float %N/A
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.9
P/FCF N/A
P/OCF N/A
P/B 16.38
P/tB 18.97
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-1.39
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.13
OCFYN/A
SpS1.43
BVpS1.22
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.6%
ROE -47.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.96%
FCFM N/A
ROA(3y)-31.61%
ROA(5y)-51.37%
ROE(3y)-603.83%
ROE(5y)-411.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.8%
GM growth 5Y-2.92%
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 1.42
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.91%
Cap/Sales 4.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.83
Altman-Z 0.99
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)666.82%
Cap/Depr(5y)645.11%
Cap/Sales(3y)567.67%
Cap/Sales(5y)856.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%138.12%
EPS Next Y61.78%
EPS Next 2Y-2.19%
EPS Next 3Y46.48%
EPS Next 5YN/A
Revenue 1Y (TTM)251.85%
Revenue growth 3Y161.25%
Revenue growth 5Y100.76%
Sales Q2Q%477.25%
Revenue Next Year120.73%
Revenue Next 2Y11.94%
Revenue Next 3Y82.7%
Revenue Next 5Y39.38%
EBIT growth 1Y59.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year66.63%
EBIT Next 3Y38.66%
EBIT Next 5YN/A
FCF growth 1Y21.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.44%
OCF growth 3YN/A
OCF growth 5YN/A